Idec Zevalin NHL Indication Split By Accelerated/Standard Approval
Executive Summary
Idec/Genentech will conduct a postmarketing study of Zevalin in non-Hodgkin's lymphoma patients who have not failed Rituxan therapy to fulfill accelerated approval requirements
You may also be interested in...
GSK/Corixa Bexxar Nuclear Pharmacy Training Kicks Off With FDA Approval
GlaxoSmithKline and Corixa's Bexxar nuclear pharmacy training program could help encourage faster uptake of the oncologic than Idec's Zevalin
GSK/Corixa Bexxar Nuclear Pharmacy Training Kicks Off With FDA Approval
GlaxoSmithKline and Corixa's Bexxar nuclear pharmacy training program could help encourage faster uptake of the oncologic than Idec's Zevalin
GSK/Corixa Bexxar User Fee Deadline Extended To Review Safety Database
FDA is extending GSK/Corixa's Bexxar user fee deadline by three months to review additional safety information on the radioimmunotherapy